Table 1.
Characteristic | |
---|---|
Sex | |
Male | 37 (45%) |
Female | 46 (55%) |
Mean age at diagnosis (y) | 17 (5.0–24.8) |
Treatment* | |
Surgery | 56 (67%) |
Enucleation | 50 (60%) |
Local resection | 6 (7%) |
Endoresection† | 2 (2%) |
Radiotherapy | 41 (49%) |
Ruthenium | 12 (14%) |
Iodine | 7 (8%) |
Brachytherapy | 3 (4%) |
Proton beam | 11 (13%) |
External beam | 3 (4%) |
Cyber knife | 3 (4%) |
Gamma knife | 2 (2%) |
Metastatic disease | |
Yes | 12 (15%) |
No | 68 (85%) |
Mean metastasis free survival (y) | 9.0 (0.01–43.7) |
Cell type | |
Spindle cell | 17 (50%) |
Epithelioid | 6 (18%) |
Mixed | 11 (32%) |
Ciliary body involvement | |
Yes | 34 (41%) |
No | 49 (59%) |
Extraocular extension | |
Yes | 7 (9%) |
No | 75 (91%) |
Mean largest basal tumor diameter (mm) | 12.7 (4.0–20.4) |
Mean maximum tumor thickness (mm) | 8.1 (1.0–20.0) |
Combined treatment in some patients.
Enucleation as secondary treatment. The total amount of patients included in this study is not represented in all categories because of missing data.